Jul 16, 2026 7:30am EDT Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement
Jul 10, 2026 4:05pm EDT Virax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds
Jul 09, 2026 1:35pm EDT Virax Biolabs Group Limited Announces Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds
Jul 09, 2026 7:30am EDT Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics
May 26, 2026 7:30am EDT Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune™ in Long COVID and Related Post-Acute Infection Syndromes
Apr 14, 2026 7:34am EDT Virax Biolabs' CEO James Foster Outlines Strategic Priorities and Near-Term Milestones in Letter to Shareholders
Mar 31, 2026 7:34am EDT Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation
Dec 04, 2025 4:05pm EST Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement
